Table 6 Comparison of Axial Elongation Among Patients Achieving Treatment Goals with 0.05% Atropine + Orthokeratology.

From: Efficacy and safety of orthokeratology sequentially combined with escalating atropine concentrations for myopia control in children

 

OK(n = 25)

OK + 0.01%ATP

OK + 0.025%ATP

OK + 0.05%ATP

F

P

(n = 25)

(n = 25)

(n = 25)

Axial elongation(mm)/6 m

0.21 ± 0.10*

0.18 ± 0.12#

0.18 ± 0.06&

0.06 ± 0.07*#&

15.5

< 0.001

Axial elongation(mm)/12 m

0.48 ± 0.15*$@

0.39 ± 0.12#$

0.37 ± 0.07&@

0.17 ± 0.09*#&

40.08

< 0.001

  1. Axial elongation(mm),6 m,6-month; 12 m,12-month; OK, orthokeratology lens; OK + 0.01%ATP, orthokeratology lens combined with 0.01% atropine eye drops; OK + 0.025%ATP, orthokeratology lens combined with 0.025% atropine eye drops; OK + 0.05%ATP, orthokeratology lens combined with 0.05% atropine eye drops; P < 0.001 Representing differences are statistically significant. *Representatives of the OK group and OK + 0.05% ATP show a statistically significant difference, #Representatives of the OK + 0.01%ATP group and OK + 0.05% ATP show a statistically significant difference, & Representative OK + 0.025% ATP and OK + 0.05% ATP have statistical differences, $ representatives of the OK group and OK + 0.01% ATP show a statistically significant difference, @ Representatives of the OK group and OK + 0.025% ATP show a statistically significant difference,
Back to article page